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Closed circular (cc) forms of extrachromosomal HIV DNA are detected in patients with high viral loads; however, it is
unclear whether these forms remain if virus replication is suppressed to undetectable levels by combination antiretroviral
therapy. A nested primer polymerase chain reaction amplification assay was used to detect the presence of ccDNA
containing two long terminal repeat sequences (2-LTR) in PBMC of patients with low or undetectable plasma HIV RNA. Fifty
percent of patients with plasma RNA levels ,50 copies/ml of blood had detectable 2-LTR DNA. Sequencing of the products
identified normal LTR–LTR junctions in the minority of cases with the majority containing anomalies including deletions and
insertions. The persistence of HIV ccDNA in patients with no detectable plasma RNA could be consistent with ongoing de
novo infection of dividing cells or with stability of this form of DNA in nondividing cells. © 2002 Elsevier ScienceIntroduction. During retroviral infections, the presence
of unintegrated extrachromosomal DNA (E-DNA) in the
infected cells has correlated with retroviral replication. In
both in vitro and in vivo HIV-1 infections, high levels of
E-DNA accumulate in the infected cell (7, 10). The E-DNA
represents either reverse-transcribed linear DNA or
closed circular forms of DNA (ccDNA). The ccDNA is
formed only after nuclear entry of fully reverse-tran-
scribed linear DNA and contains either a single copy or
a tandem double copy of the long terminal repeat (cc1-
LTR or cc2-LTR, respectively) (1). For this reason ccDNA
is considered a marker of nuclear entry. The ccDNA end
products, detected in in vitro infections, are thought to be
unstable terminal products of the reverse transcription
process with a short half-life as determined by measure-
ment in acute infection of replicating T-cells (8, 11). This
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1instability in replicating T-cells, which could be due to
either dilution from cell division and cell death or inher-
ent instability of the DNA, suggests that the presence of
ccDNA in PBMC could be used as a marker for ongoing
generation of newly infected cells in vivo. However, the
stability and half-life of HIV ccDNA in nonreplicating cells
has not been similarly characterized and could be a
reservoir of persistent ccDNA.
HIV-1-infected individuals maintained on a highly ac-
tive antiretroviral regimen may experience prolonged vi-
ral suppression with no detectable plasma viral RNA as
determined by highly sensitive methods capable of de-
tecting as little as 50 copies/ml of blood (12). Neverthe-
less, these patients harbor reservoirs of replication-com-
petent virus because most patients experience transient
or sustained breakthrough of replicating virus after sus-
pension of antiretroviral therapy (4–6, 13). It is still not
clear whether suppression of virus replication by antivi-
rals would lead to a loss of HIV ccDNA. Using a sensitive
assay that specifically detects the cc2-LTR, we show the
presence of ccDNA in PBMC of patients with no detect-
able plasma viral RNA on highly active antiretroviral
therapy (HAART). We also show sequence heterogeneity
at the LTR–LTR junction in this population.
Results. Thirty-six patients were evaluated in this
study. While 77% of the patients had plasma viral RNA
levels ,50 copies/ml (Table 1), nine patients had low
levels of detectable viral RNA at the time of analysis
ranging from 57 to 7931 copies/ml of blood and one had
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2 RAPID COMMUNICATIONa level of 19,429 copies/ml. All patients were on combi-
nation antiretroviral regimens and most received D4T,
3TC, and a protease inhibitor. The mean CD41 cell count
for those with viral RNA levels ,50 copies/ml was 505
cells/mm3 and the mean duration for viral loads ,400
TABLE 1
HIV-1-Positive Patients on HAART from Jack Martin Fund Clinic
at Mount Sinai Medical Center
Sample
No.
CD4 count
(cells/mm3)
Viral load
(copies/ml)
Duration in
months of viral
load ,400
copies/ml
Antiretroviral
regimen
1 674 ,50 D4T/3TC/NVP
2 490 ,50 6 D4T/3TC/IND
3 673 87 3 D4T/3TC/DDI/NVP
4 566 ,50 20 AZT/3TC/NLF
6 774 ,50 9 D4T/3TC/NLF
7 162 ,50 7 D4T/3TC/NLF
8 313 ,50 24 AZT/3TC/IND
9 538 83 D4T/3TC/IND
10 614 ,50 18.5 AZT/3TC/IND
11 462 ,50 8 D4T/3TC/IND
12 429 ,50 14 AZT/3TC
13 417 ,50 10.5 D4T/3TC/NLF
14 777 ,50 7 D4T/3TC/SQV
15 988 ,50 23 AZT/3TC/IND
16 445 ,50 17 D4T/3TC/IND
17a 730 149 17.5 D4T/3TC/IND
18 592 ,50 6.5 D4T/3TC/IND
19 145 ,50 24.5 D4T/3TC/IND
20 423 ,50 18.5 D4T/3TC/IND
22 150 7,931 D4T/3TC/NLF
23 372 ,50 8.5 D4T/3TC/NLF
24 33 ,50 25.5 AZT/3TC/IND/NVP
30 425 ,50 11 D4T/3TC/IND/EFV
31 423 ,50 4 D4T/3TC/IND
34 254 57 2 D4T/3TC/EFV
35 305 ,50 20 AZT/3TC/NLF
37a 143 1591 AZT/3TC/NLF
38 341 ,50 19 AZT/3TC/IND/EFV
39 887 ,50 20 D4T/3TC/NLF
40a 395 86 D4T/3TC/NLF
41 420 ,50 D4T/3TC/NLF
42 216 ,50 6.5 D4T/3TC/NLF
43 450 ,50 16.5 AZT/3TC/IND
46a 236 19,429 D4T/3TC/IND/EFV
47a 385 197 2.5 AZT/3TC/NLF
48 973 ,50 6.5 D4T/RTV/SQV
49 666 ,50 27.5 AZT/3TC/IND
50 396 ,50 6.5 AZT/3TC/NLF/NVP
51 984 ,50 1.5 AZT/DDI/SQV
Note. D4T, Stavudine; NVP, Nevirapine; 3TC, Lamivudine; EFV, Efa-
virenz; DDI, Didanosine; IND, Indinavir; AZT, Zidovudine; NLF, Nelfina-
vir; SQV, Saquinavir; RTV, Ritonavir. Mean CD4 count: 505 cells/mm3;
mean duration viral load: ,400 copies/ml at 13 months (does not
include controls or missing data).
a Controls for positive ccDNA.copies/ml was 13 months. The higher viral load cutoff
was used to calculate duration of suppression becausethe ultrasensitive assay had been introduced in the clinic
only within the past year.
Patient samples from the 32 patients contained low-
molecular-weight DNA as indicated by the presence of
mitochondrial DNA. Sixteen of the 32 patients with E-
DNA (50%) had detectable cc2-LTR forms (Fig. 1). Of the
patients with ,50 copies of HIV RNA/ml of blood, 50%
had detectable cc2-LTR. In all cases, the DNA was ex-
tracted from a starting cell count of 2 3 106 PBMC,
indicating a frequency of at least 1–2/106 cells containing
cc2-LTR DNA.
Figure 1 shows that, in addition to the expected 120-bp
product, the nested PCR generated several other prod-
ucts that hybridized to the LTR–LTR junction probe under
stringent conditions (data not shown). Reaction products
were gel-purified and sequence analyses of multiple
clones from different PCRs were performed. The ;60-bp
product consisted of 10–15 bp of non-HIV sequence
flanked by 477/516 primer sequences and so was con-
sidered an artifact of the PCR (Fig. 1). The 120-bp prod-
ucts contained the heterogeneous LTR–LTR junction se-
quences. In 6 of 8 patients there were short insertions at
the junction (Fig. 2), and in one patient (No. 11) there was
a small deletion at the junction. Thus, only 1 patient had
the expected circular junction. The two larger PCR prod-
ucts, 140 and 170 bp, were also detected along with the
expected 120-bp product in 10 patient samples (asterisks
for patient 6 in Fig. 1 show typical products). These
products contained reiterations of the 477 and 516 primer
sequences at the LTR–LTR junction site. Multiple inde-
pendent PCR amplifications of patient samples showed
that generation of the ;60-bp products was not repro-
ducible for a given patient, whereas generation of the
expected 120-, 140-, and 170-bp products was reproduc-
ible. Also, independent clones from independent PCR
assays showed consistent junction insert sequences for
the multiple products, making it unlikely that they are
artifacts of PCR amplification. Therefore, the sequence
data indicate that sequence variability exists at the junc-
tions of cc-2LTR forms in our patient population.
Discussion. At least 50% of patients with viral plasma
RNA levels below the limits of detection had detectable
2-LTR circular E-DNA. If this form of DNA is derived from
replicating T cells, this observation is consistent with
significant ongoing virus replication and generation of
newly infected cells in our patient population despite the
presence of potent antiviral drugs (11). This is the case
following the in vitro infection of replicating T-cells (10).
However, it is possible that this E-DNA is not derived
from actively replicating cells. The stability and longevity
of ccE-DNA in nondividing cells are not as clearly de-
fined and could in fact be prolonged. If there was a
population of cells within PBMC where these forms are
more stable, the utility of the assay for monitoring ongo-
ing viral infection would be limited.
e 150- a
o DNA
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and with one exception, these patients had no detect-
able plasma RNA either. Although it is possible that the
absence of cc2-LTR may merely represent a sampling
error due to the starting cell number, recent observations
by Sharkey et al. (11) suggest that there may be a small
number of patients who have more complete viral sup-
pression. In an analysis similar to that reported here,
they noted that three of four patients lacking cc2-LTR
DNA had no replication-competent virus in a high-input
viral coculture assay.
It is possible that the junctions formed result from
ligation of unintegrated viral DNA ends that are integra-
tion-defective. Of the eight samples sequenced, only one
(No. 1) contained the predicted circular junction (GT/AC).
The other seven samples showed heterogeneous 1- to
9-bp insertions and in one case a 13-bp deletion. These
various classes of junctions do not result in the joining of
normal, unprocessed LTR termini. Patients 2 and 6, for
example, have a stretch of purines inserted into the
junction, possibly arising from the incomplete removal of
the tRNA primer during reverse transcription (9). The
deletion may have resulted from aberrant plus-strand
FIG. 1. Nested PCR with cc-2LTR-specific primers from extrachromos
1). Patients 47, 49, 50, and 51 were indeterminant based on being nega
2LTR, predicted 120-bp junction product. Asterisks on sample 6 indicat
2LTR junction. 1, control 2-LTR junction template from pTA2LTR. 2, n
FIG. 2. 2-LTR circle junction sequences amplified from extrachromo-
somal DNA of eight HIV-1-infected individuals using 2-LTR circle-spe-
cific primers described in the legend to Fig. 3.initiation, with initiation at a triplet of G residues down-
stream of the expected origin. These various LTR termi-
nal sequences lack the conserved residues that act as
substrates for integration and, therefore, may end up as
substrates for the formation of closed circular DNA. A
study on simian immunodeficiency virus of pig-tailed
macaques also showed sequence heterogeneity in cir-
cle junctions (9). The sequence data derived from our
patient population displayed sequence heterogeneity
across the circle junction with the majority of clones
lacking the normal unprocessed ends for ligation as
seen in vivo with SIV infection. This junction sequence
heterogeneity precludes the use of a junctional probe to
detect the presence of closed circular DNA in patients.
Larger studies with long-term follow-up will be needed
to determine whether the absence of cc2-LTR DNA in
PBMC predicts a better therapeutic outcome. Longitudi-
nal in vivo and in vitro studies are required to address
whether these circular forms are stable in different cell
types and to determine whether the presence or ab-
sence of ccDNA is predictive of the duration of viral
suppression.
Materials and Methods. Patient selection and sample
collection. Patients from the Jack Martin Fund Clinic at
Mt. Sinai Medical Center having their most recent
plasma HIV RNA level ,50 copies/ml were asked to
participate in this study. After informed consent was
obtained from the patient, 10 ml of whole blood was
collected in an acid citrate-containing tube and a de-
tailed history of antiretroviral medications was recorded.
Plasma was separated by centrifugation and PBMC were
isolated using Ficoll Hypaque gradient centrifugation.
After separation, cells were pelleted by centrifugation;
both plasma and cell pellets were frozen at 280°C until
analysis.
Plasma HIV RNA Levels. Plasma RNA levels were de-
NA of 36 HIV-1-infected individuals (patient number as shown in Table
both mitochondrial DNA and cc-2LTR. Arrow A, ;60-bp PCR artifacts.
nd 210-bp products containing reiterated primer sequences within the
template. 100-bp marker bands are shown to the right.omal D
tive fortermined on the same sample processed for the ccDNA
assay utilizing an ultrasensitive Amplicor HIV-1 Monitor
showin
4 RAPID COMMUNICATIONtest (Roche Molecular Systems, Branchburg, NJ) with a
lower limit of detection of 50 copies/ml of blood.
ccDNA Detection. To enrich for E-DNA, low-molecular-
weight DNA was extracted from the cell pellet using an
alkaline-SDS-based DNA extraction kit from Qiagen
(Valencia, CA). A nested PCR was used to detect the
cc2-LTR forms of E-DNA. The first PCR was performed
using the primer pair 9600/515, amplifying a fragment of
DNA of 217 basepairs encompassing the junction be-
tween the 39 and the 59 LTR in the cc2-LTR (Fig. 3A). The
PCR parameters were as follows: 1 min at 94°C, 1 min at
62°C, 1 min at 72°C for 35 cycles followed by a single
cycle of 15 min at 72°C using 10 pmol of each primer:
primer 9600, 59-GCT TAA GCC TCA ATA AAG CTT GCC
T-39, corresponding to nt 9600–9624 in the HXB2c DNA
sequence, in the sense orientation; primer 515, 59-GTG
TGT AGT TCT GCT AAT CAG GGA A-39, corresponding to
nt 72–96 in the HXB2c nucleotide sequence, in the anti-
sense orientation. The DNA products were purified on a
Qiagen DNA purification column. Twenty microliters of
each eluate (of a total of 50 ml) was used in a second
nested PCR using 50 pmol each of the internal primers,
477/516, resulting in 120 bp (Fig. 3A). Primers and PCR
conditions for this second PCR were as previously de-
FIG. 3. (A) Schematic diagram of PCR strategy for amplification of cc-
477/516. Expected PCR product with nested PCR is 120 bp. (B) Sensitivi
(starting at 103 copies) were amplified with primer 9600/515 as describ
then subjected to secondary PCR with internal primers 516/477 (right),
one plasmid copy. M, 100-bp ladder.scribed (2). PCR products were analyzed by electro-
phoresis on 2% agarose gels. Bands were confirmed byhybridization as previously described using the 477/516
PCR product as probe (2).
Cloning of Nested PCR Product. Nested PCR prod-
ucts from HIV-1-positive patients were cloned into the
pGEM-T Easy vector (Promega, Madison, WI). Plasmids
were isolated with the Qiagen miniprep purification kit
(Qiagen) and were digested with SphI and NdeI to con-
firm insertion of nested PCR products.
Sequencing of Cloned Nested PCR Product. Plasmid
DNAs were sequenced with T7/SP6 primers using an
ABI/Prism 377 DNA sequencer (Perkin–Elmer).
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